Overcoming challenges in ophthalmology.
The pharmaceutical industry’s significant investment in ophthalmic diseases is relatively new. The first pharmacotherapy for neovascular age-related macular degeneration (neovascular AMD), the leading cause of blindness, was introduced within the last decade. PanOptica and other researchers are now working to apply advances in other therapeutic categories to ophthalmology by repurposing therapies developed for diseases ranging from cancer to inflammation. PanOptica has the scientific and commercial expertise needed for this task.
Drug delivery is another key challenge in developing effective, safe and convenient therapies for eye diseases. Nearly 100 years ago, the first therapy for glaucoma, a common ocular disorder, was made widely available. This treatment came in the form of an eye drop, which remains the most popular delivery mechanism for ophthalmic medicine today because it is easy to administer and comfortable for the patient. Unfortunately, some chemical compounds do not lend themselves well to eye drop delivery. Some are highly water insoluble, while others are unstable and can degrade quickly at room temperature.
Today, newer technologies are becoming available that overcome this challenge. Companies are exploring the use of gene delivery to bring small molecules, antibodies, and other novel therapies to targets in the eye with precision and safety. Some of these technologies hold the promise of extended-release delivery, potentially improving efficiency and reducing patient burden. Other technologies may help deliver medication internally to the eye, potentially enhancing surgical outcomes. At PanOptica, we are interested in all of these modalities. Our objective is to pursue those compounds that hold the greatest potential benefit for patients and providers.
Contact us to learn more about development opportunities in collaboration with PanOptica.